• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Pre-Market Session

    6/28/23 9:12:32 AM ET
    $CBUS
    $CGTX
    $ETON
    $GNPX
    Agricultural Chemicals
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CBUS alert in real time by email

    Gainers

    • Theriva Biologics (AMEX:TOVX) shares moved upwards by 45.0% to $1.2 during Wednesday's pre-market session. The market value of their outstanding shares is at $18.1 million.
    • Minerva Neurosciences (NASDAQ:NERV) shares increased by 34.55% to $8.1. The company's market cap stands at $45.1 million.
    • OPKO Health (NASDAQ:OPK) stock rose 18.07% to $1.96. The market value of their outstanding shares is at $1.5 billion.
    • Vincerx Pharma (NASDAQ:VINC) shares increased by 15.15% to $1.52. The market value of their outstanding shares is at $32.2 million.
    • Cibus (NASDAQ:CBUS) stock moved upwards by 13.49% to $11.35. The company's market cap stands at $188.2 million.
    • Genprex (NASDAQ:GNPX) stock rose 12.55% to $0.83. The company's market cap stands at $43.2 million.

    Losers

    • Sonnet BioTherapeutics (NASDAQ:SONN) shares decreased by 25.1% to $0.51 during Wednesday's pre-market session. The market value of their outstanding shares is at $13.8 million.
    • Eton Pharmaceuticals (NASDAQ:ETON) shares declined by 19.56% to $3.25. The market value of their outstanding shares is at $82.8 million.
    • Tivic Health Systems (NASDAQ:TIVC) shares fell 13.3% to $0.12. The market value of their outstanding shares is at $3.5 million.
    • Surgalign Holdings (NASDAQ:SRGA) stock declined by 10.78% to $0.24. The company's market cap stands at $2.2 million.
    • Prenetics Global (NASDAQ:PRE) stock declined by 10.13% to $0.8. The market value of their outstanding shares is at $127.6 million.
    • Cognition Therapeutics (NASDAQ:CGTX) shares fell 9.2% to $2.27. The company's market cap stands at $66.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CBUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CBUS
    $CGTX
    $ETON
    $GNPX

    CompanyDatePrice TargetRatingAnalyst
    Prenetics Global Limited
    $PRE
    3/16/2026$29.00Buy
    Lake Street
    Prenetics Global Limited
    $PRE
    2/11/2026$36.00Buy
    Roth Capital
    OPKO Health Inc.
    $OPK
    11/20/2025Neutral
    Analyst
    OPKO Health Inc.
    $OPK
    10/31/2025$1.60Buy → Hold
    Jefferies
    OPKO Health Inc.
    $OPK
    4/25/2025Neutral
    Analyst
    Eton Pharmaceuticals Inc.
    $ETON
    1/23/2025$17.00 → $33.00Buy
    H.C. Wainwright
    Eton Pharmaceuticals Inc.
    $ETON
    1/10/2025$21.00Buy
    B. Riley Securities
    Eton Pharmaceuticals Inc.
    $ETON
    1/6/2025$15.00 → $17.00Buy
    H.C. Wainwright
    More analyst ratings

    $CBUS
    $CGTX
    $ETON
    $GNPX
    SEC Filings

    View All

    Theriva Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Theriva Biologics, Inc. (0000894158) (Filer)

    3/23/26 8:10:12 AM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tivic Health Systems Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/20/26 5:15:08 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form EFFECT filed by Minerva Neurosciences Inc

    EFFECT - Minerva Neurosciences, Inc. (0001598646) (Filer)

    3/20/26 12:15:13 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBUS
    $CGTX
    $ETON
    $GNPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Prenetics Group Ltd. with a new price target

    Lake Street initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $29.00

    3/16/26 8:45:09 AM ET
    $PRE
    Blank Checks
    Finance

    Roth Capital initiated coverage on Prenetics Group Ltd. with a new price target

    Roth Capital initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $36.00

    2/11/26 7:52:37 AM ET
    $PRE
    Blank Checks
    Finance

    Analyst initiated coverage on Opko Health

    Analyst initiated coverage of Opko Health with a rating of Neutral

    11/20/25 8:08:07 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBUS
    $CGTX
    $ETON
    $GNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Paganelli John A

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    3/20/26 4:25:05 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Uppaluri Subbarao V

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    3/20/26 4:16:55 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Uppaluri Subbarao V

    3 - OPKO HEALTH, INC. (0000944809) (Issuer)

    3/20/26 4:10:17 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBUS
    $CGTX
    $ETON
    $GNPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & Chairman Frost Phillip Md Et Al bought $768,807 worth of shares (580,000 units at $1.33) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/21/25 5:07:09 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Frost Phillip Md Et Al bought $771,328 worth of shares (580,000 units at $1.33) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/20/25 6:10:53 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Frost Phillip Md Et Al bought $759,115 worth of shares (580,000 units at $1.31) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/19/25 5:02:21 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBUS
    $CGTX
    $ETON
    $GNPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma

    – Successful meeting with FDA enables advancement into proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC – – Combined feedback from FDA and previously from EMA enables company to finalize protocol for pivotal Phase 3 clinical trial while pursuing strategic funding opportunities ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the outcomes of a recent Type B End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug

    3/23/26 8:00:00 AM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

    PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), plans to release financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 26, 2026 before the market open. Management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating results and provide a business update.    Conference Call InformationTo participate in the conference call, dial (800) 445-7795 (U.S.) or (785) 424-1699 (international) and provide conference ID number CGTXQ4. The webc

    3/23/26 7:30:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.19, and Adjusted EBITDA of $6.2 millionLaunched DESMODA™, the first and only FDA-approved desmopressin oral solutionLicensed U.S. rights to Orphan Drug HEMANGEOL®; expected to be accretive to 2026 earningsCompany expects full year 2026 revenue to exceed $110 million with an Adjusted EBITDA margin of over 30%Management to hold conference call today at 4:30pm ET DEER PARK, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovati

    3/19/26 4:05:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBUS
    $CGTX
    $ETON
    $GNPX
    Financials

    Live finance-specific insights

    View All

    Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

    PURCHASE, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), plans to release financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, March 26, 2026 before the market open. Management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating results and provide a business update.    Conference Call InformationTo participate in the conference call, dial (800) 445-7795 (U.S.) or (785) 424-1699 (international) and provide conference ID number CGTXQ4. The webc

    3/23/26 7:30:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024Q4 2025 basic GAAP EPS of $0.06, fully diluted GAAP EPS of $0.05, basic non-GAAP EPS of $0.21, fully diluted non-GAAP EPS of $0.19, and Adjusted EBITDA of $6.2 millionLaunched DESMODA™, the first and only FDA-approved desmopressin oral solutionLicensed U.S. rights to Orphan Drug HEMANGEOL®; expected to be accretive to 2026 earningsCompany expects full year 2026 revenue to exceed $110 million with an Adjusted EBITDA margin of over 30%Management to hold conference call today at 4:30pm ET DEER PARK, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovati

    3/19/26 4:05:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

    - Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma - - Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential milestones plus royalties on commercial sales - - Cash and cash equivalents of $13.1 million as of December 31, 2025; recent capital raises increase cash to $15.2 million as of February 26, 2026 and provides cash runway into Q1 2027- ROCKVILLE, M.D., March 12, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported fin

    3/12/26 8:00:00 AM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CBUS
    $CGTX
    $ETON
    $GNPX
    Leadership Updates

    Live Leadership Updates

    View All

    Formula 1 Phenom Ollie Bearman Joins Prenetics' IM8 Health as Global Ambassador and Shareholder

    Ollie Bearman becomes the latest elite athlete to invest in NASDAQ:PRE, underscoring a deep belief in the brand's mission and products.IM8, co-founded by David Beckham, continues to attract top-tier athletes who prioritize scientifically validated and trusted nutritional support.IM8 has become one of the fastest-growing supplement brands globally, achieving an extraordinary US$100 million in Annual Recurring Revenue in just 11 months from launch.Bearman's rapid rise – including a historic points-scoring Ferrari debut at just 18—cements his reputation as one of motorsport's brightest young talents. NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE), a leading

    2/13/26 8:00:00 AM ET
    $PRE
    Blank Checks
    Finance

    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors

    BURLINGTON, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment of Dr. Inderjit Kaul, Chief Medical Officer of Draig Therapeutics, to the board of directors. Dr. Kaul will also serve as a consultant to the Company for the future clinical development of roluperidone. Last month, the Company announced successfully raising up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone for the treatment of negative symptoms in patients with schizophrenia, resubmission of it

    11/19/25 8:30:00 AM ET
    $NERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cibus Announces the Election of Craig Wichner to Board of Directors

    SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced the election of Craig Wichner to its Board of Directors. Mr. Wichner will also serve as a member of the Board's current Strategy Committee. "Craig brings an exceptional combination of financial acumen, strategic discipline, and industry insight to the Cibus Board," said Mark Finn, Chairman of the Board of Cibus. "As Cibus prepares for anticipated commercial scaling of our trait platform, Craig's expertise in sustainable growth and capital strategy in agriculture will be instrumental in strengthening our

    11/11/25 7:00:00 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    $CBUS
    $CGTX
    $ETON
    $GNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Eton Pharmaceuticals Inc.

    SC 13G - Eton Pharmaceuticals, Inc. (0001710340) (Subject)

    12/9/24 4:04:43 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by OPKO Health Inc.

    SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/15/24 4:39:33 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Vincerx Pharma Inc.

    SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)

    11/14/24 3:39:40 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care